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Submitted Mar 11, 2013; accepted Jun 5, 2013.DISCUSSIONDr Julie Ann Freischlag (Baltimore, Md). Could you deﬁne
how a myocardial infarction was determined, and what you
required in order to make that diagnosis?
Dr Jessica P. Simons. The way that the data capture postop-
erative myocardial ischemia are categorized as none, troponin
elevation only, or clinical or EKG evidence of MI.
Myocardial infarction is deﬁned at the discretion of the
surgeon, ultimately, when they ﬁll out the data sheets, but it
includes either clinical evidence of myocardial infarction, such as
chest pain or EKG changes consistent with an MI.
Dr Jon Matsumura (Madison, Wisc). What are the criteria to
screen a patient with a troponin? Were you only testing patients
who had symptoms, or was it all the patients in the database had
a routine troponin? With a prophylactic operation for aneurysm
repair or asymptomatic carotid, predicting the long-term survival
is helpful for the patient decision making.
Dr Simons. I think that’s a really excellent point, and that it
would be really helpful to know what the indication was. We don’t
have that data available to us, why a patient would have had tropo-
nins checked postoperatively. It’s not a routine part of the manage-
ment of all patients in the VSGNE, but rather, it’s at the discretion
of the surgeon.
Dr Michael Conte (San Francisco, Calif). I think that your
slide where you contrasted the implications about causality versus
association is really the most important point, because I think,
again, this information may be misinterpreted in light of the types
of conversations that surround it; for example, the CREST end
point.
And, unfortunately, your conclusion slide actually erred back
in the wrong direction by suggesting causality, the way I read it,
when you said that these postoperative events were themselves
directly related to later mortality. I think if you took 1000 cardio-
vascular patients in the clinic and gave them all a stress test, it
would be no shock to ﬁnd out that the ones that failed the stress
test would not have quite as good long-term survival as those
that passed the stress test. But, the stress test doesn’t cause the
death. That is entirely analogous to the issue with the majority
of postoperative MIs.
I think that this becomes a critical issue with interpretation of
the ﬁndings, while I concur with the importance of working to
prevent these events. My major question to you is: did you look
at whether or not all of the patients were treated according to
guidelines with cardioprotective medications? Because I think
that really is the bottom line for perioperative management. It’s
not the procedure that’s causing the late mortality, it’s really
whether or not they are getting appropriate medical care before,
during, and after.
Dr Simons. We did take a look to some extent at that,
although I think that that question is being addressed a little bitmore thoroughly with another VSGNE study. But, in brief, we
did ﬁnd that the use of statin and antiplatelet agents at the time
of discharge was protective against death in our Cox proportional
hazard model, suggesting exactly as you’re saying, that if patients
are treated medically more appropriately, then perhaps that would
be what impacts survival over the long term.
Dr John Chang (Roslyn, NY). What would be your sugges-
tions in terms of optimization preoperatively? Do you think that
everybody who has a positive stress test should go through cardiac
catheterization or revascularization?
Dr Simons. Well, I think we probably need to lean on our
cardiology colleagues a little bit more in order to ﬁgure out exactly
what the right things would be to better preoptimize patients
preoperatively and medically manage them postoperatively as
well. Certainly the data suggest a beneﬁt to medications such as
statins and antiplatelet agents for improving survival. But, beyond
that, who needs a stress test and who needs preoperative cardiac
catheterization is a question I would work with our cardiology
colleagues to better answer.
Dr Matthew Eagleton (Cleveland, Ohio). When you’re look-
ing at cause of death at 5 years, do you have any categorization as
to cause of death, such as cardiovascular death versus cancer death?
Dr Simons. We don’t have that data available to us in this
data set.
Dr Cheong Lee (Milwaukee, Wisc). Elevation in troponin can
be also related to impairment in renal function, so do you think
this is actually a reﬂection of renal impairment that you’re seeing
the elevations in troponin being related with mortality?
Dr Simons. I think it’s a little hard to know for sure. I know
that looking through our data, the percentage of patients who have
signiﬁcant renal diseaseewhich is deﬁned by a creatinine greater
than 1.8eis very small, so I suspect that that inﬂuence would be
very minor. But, that is a reasonable point.
The other confounding issue is whether troponins were
checked disproportionally among those patients with renal failure,
which would bias the data. So, I can’t really answer that question
speciﬁcally.
Dr Amy Reed (Hershey, Pa). I’m assuming this is from the
VSGNE database. And, I know on a VQI, we do put down
whether there has been any preoperative evaluation. Was that
not available in this data set that you aren’t aware of that?
Dr Simons. No, we did have access to that variable. And,
we did include in some of our analyses whether or not a preop-
erative stress test was performed. And, it was not performed for
the majority of patients. I think it was positive only in an
extremely small percentage, as you would expect to ﬁnd.
Regardless, it ultimately didn’t end up being signiﬁcant on
univariate screening, and that’s why it didn’t make it into the
ﬁnal analysis.
